Evidence map›Paper›PMID 36620620›Full record

ArticleFrontiers in cardiovascular medicine2022

The influence of testosterone on the risk of cardiovascular events after percutaneous coronary intervention.

Cheng-Hung Chiang, Wan-Ting Hung, En-Shao Liu, Tse-Hsuan Yang, Chin-Chang Cheng, Wei-Chun Huang, Guang-Yuan Mar, Feng-Yu Kuo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Cheng-Hung ChiangCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Wan-Ting HungDepartment of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
En-Shao LiuCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Tse-Hsuan YangCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Chin-Chang ChengCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Wei-Chun HuangCollege of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Guang-Yuan MarCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Feng-Yu KuoCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Kaohsiung Veterans General Hospital · TWNational Yang Ming Chiao Tung University · TWFooyin University · TWTajen University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methods: Between 2015 and 2018, 580 men undergoing PCI at a tertiary referral hospital were divided into low (<3.25 ng/mL) and normal (≥3.25 ng/mL) testosterone groups. Major adverse cardiovascular event (MACE) was defined as the composite outcome of CV death, myocardial infarction, and target lesion revascularization/target vessel revascularization (TLR/TVR) during up to 48 months follow-up after PCI. Results: There were 111 and 469 patients in the low and normal testosterone groups, respectively, with the overall MACE rate of the former being higher than the latter (26.13% vs. 13.01%, Conclusion: Low serum testosterone concentrations were associated with a higher risk of MACE and TLR/TVR after PCI than those with normal testosterone levels.

Indexed as

coronary artery diseaseEPI—epidemiologymajor adverse cardiovascular eventspercutaneous coronary interventiontestosterone

Identifiers

PMID36620620
PMCPMC9815835
OpenAlexW4312187783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.